Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post …,

HOUSTON, July 6, 2021 /PRNewswire/ — Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the …, HOUSTON, July 6, 2021 /PRNewswire/ — Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the …, Read More

Scroll to Top